HemoSonics LLC
31
0
0
26
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
12.9%
4 terminated/withdrawn out of 31 trials
86.7%
+0.2% vs industry average
0%
0 trials in Phase 3/4
8%
2 of 26 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (31)
Reference Range Study for the Quantra System With the QPlus Cartridge in Pediatric Patients
Role: lead
QStat Cartridge in Obstetric Patients
Role: lead
Reference Range Study for the Quantra System With the QStat Cartridge in Obstetric Patients
Role: lead
Evaluation of Novel Point of Care Coagulation System in Pregnant Women
Role: collaborator
Quantra® System With the QStat® Cartridge in Trauma
Role: lead
Quantra QStat Sample Type Comparison
Role: lead
Evaluation of the Quantra QStat System in Obstetric Patients
Role: lead
Clinical Evaluation of the Hemosonics Quantra® Coagulation Monitor in Liver and Multivisceral Transplantation
Role: collaborator
Exploratory Assessment of the Quantra® System in Adult ECMO Patients
Role: lead
QPlus Pediatric Reference Interval
Role: lead
Quantra QStat in Trauma and Liver Transplant
Role: lead
Quantra QPlus Sample Type Comparison
Role: lead
Use of the Quantra QPlus Sytem in Cardiac Surgery
Role: lead
Coagulation Changes Associated With COVID-19 Infection
Role: lead
QStat in Liver Transplant
Role: lead
QStat in Trauma and Obstetric Hemorrhage
Role: lead
Evaluation of the Quantra System in a Surgical Oncological Population
Role: lead
QStat Pilot Reference Range Study
Role: lead
Reference Range Study for the Quantra QStat System
Role: lead
Validation of a Quantra Supported Hemotherapy Algorithm in Cardiac Surgery
Role: collaborator